Jefferies analyst Roger Song has maintained their bullish stance on UTHR stock, giving a Buy rating on June 5.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roger Song has given his Buy rating due to a combination of factors that highlight United Therapeutics’ strong market position and growth potential. Despite emerging competition from TPIP, which has shown promising Phase 2 results, it will take several years for TPIP to reach the market due to the need for extensive Phase 3 trials. This delay allows United Therapeutics to continue strengthening its presence in the PAH/PH-ILD market with Tyvaso, which has established brand equity and patient preference.
Furthermore, United Therapeutics is expanding Tyvaso into new indications such as IPF and PPF, with significant data expected in the coming years. The company is also developing a robust prostacyclin pipeline, including new oral and inhaled formulations. Additionally, the potential for transformative xenotransplant developments adds to the company’s long-term growth prospects. These strategic initiatives suggest significant room for market penetration and growth, supporting the Buy rating.
Song covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, United Therapeutics, and TG Therapeutics. According to TipRanks, Song has an average return of -18.7% and a 30.69% success rate on recommended stocks.
In another report released on June 5, Leerink Partners also reiterated a Buy rating on the stock with a $418.00 price target.